Last reviewed · How we verify

NCT00004414

Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis

Completed NA Last updated 24 March 2015
What this trial tests

NA trial testing sincalide in Cholestasis in 252 participants. Completed in 1 June 2002.

Timeline
1 September 1997
1 June 2002

Quick facts

Lead sponsorUniversity of Michigan
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Maskingdouble
Primary purposetreatment
Enrollment252
Start date1 September 1997
Estimated completion1 June 2002
Sites6 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Michigan

Who can join

Under 30 Days, any sex, with Cholestasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

OBJECTIVES: I. Compare conjugated bilirubin levels and serum bile acid levels in severely premature newborns on long term parenteral nutrition and given either sincalide or placebo. II. Compare morbidity and mortality rates in this patient population. III. Evaluate ultrasonographic images of the hepatobiliary tree during and 1 to 2 years after the administration of sincalide or placebo to assess the development of biliary sludge and biliary stone formation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cholestasis

Currently open trials in the same condition.

Other University of Michigan trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00004414.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing